BTIG Starts Quoin Pharmaceuticals Coverage With Buy Rating
BTIG initiated coverage of Quoin Pharmaceuticals with a Buy rating and set a $14.00-a-share target, Dow Jones Newswires and Benzinga reported.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
BTIG initiated coverage of Quoin Pharmaceuticals with a Buy rating, Dow Jones Newswires reported, citing ratings information from Benzinga.
The investment bank set a price target of $14.00 per share for the company. The ratings action was listed on Benzinga’s QNRX analyst-ratings page.
why it matters
The announcement marks a new analyst view of Quoin Pharmaceuticals and may draw market attention to the company’s shares and valuation.
instruments
sources
- Quoin Pharmaceuticals Price Target Announced at $14.00/Share by BTIG — Dow Jones Newswires, 12 October 2026 at 10:29 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗